Yang LL, et al. - Researchers sought to detect the immunoreactivity of CD317 in human head and neck squamous cell carcinoma (HNSCC) tissue microarrays, which contained 43 oral mucosa samples, 48 dysplasia samples, and 165 primary HNSCC. Up-regulated CD317 expression was observed in HNSCC tumor cells, and the CD317 expression level was noted to be independent of the histological grade, tumor size, and lymph node metastasis. In this patient cohort, overexpression of CD317 was noted to indicate poor prognosis and was associated with immune-related components. They suggested CD317 as a potential target for effective immunotherapy of HNSCC.